Skip to main content

Advertisement

SpringerLink
Log in

Cell-Signaling Therapy in Rheumatoid Arthritis

  • RHEUMATOID ARTHRITIS (LW MORELAND, SECTION EDITOR)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

New treatments for rheumatoid arthritis (RA) continue to emerge to meet unsatisfied needs of a significant number of patients. The development of new, oral biologic therapy is a significant step forward, although these drugs will require further evaluation in clinical settings before their true potential is appreciated. This new, oral biologic therapy has mostly focused on inhibition of intracellular signaling. These mechanisms and the available studies regarding the efficacy and safety of specific drugs which interfere with these mechanisms are the subject of this article.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Cohen S, Fleischmann R. Kinase inhibitors: a new approach to rheumatoid arthritis. Curr Opin Rheumatol. 2010;22:330–6.

    Article  PubMed  CAS  Google Scholar 

  2. Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, et al. Modulation of inate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186:4234–43.

    Article  PubMed  CAS  Google Scholar 

  3. Choi SI, Brahn E. Rheumatoid Arthritis therapy: advances from bench to bedside. Autimmunity. 2010;43:1–15.

    Article  Google Scholar 

  4. Kaminska B, Swiatek-Machado K. Targeting signal pathways with small molecules to treat autoimmune disorders. Expert Rev Clin Immunol. 2008;4:93–112.

    Article  PubMed  CAS  Google Scholar 

  5. Riese RJ, Krishnaswami S, Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol. 2010;24:513–26.

    Article  PubMed  CAS  Google Scholar 

  6. Walker JG, Smith MD. The JAK-STAT pathway in rheumatoid arthritis. J Rheumatol. 2005;32:150–3.

    Google Scholar 

  7. Zerbini CA, Lamonte AB. Tofacitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2012;8:319–31.

    Article  PubMed  CAS  Google Scholar 

  8. •• Okamoto H, Kobayashi H. Tyrosine kinases in rheumatoid arthritis. J Inflammation. 2011;8:1–7. An excellent review of the immuno-pathologic role of JAKs and ways in which their inhibition might be beneficial in RA.

    Article  Google Scholar 

  9. Rosengren S, Corr M, Firestein GS, Boyle DL. The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autokine role of type I interferon. Ann Rheum Dis. 2012;71:440–7.

    Article  PubMed  CAS  Google Scholar 

  10. • Labranche TP, Jesson MI, Radi ZA, et al. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum. 2012;64:3536–42. An important observation potentially explaining how tofacitinib might have potentially important effects on bone damage in RA.

    Article  Google Scholar 

  11. Fleischmann R, Cutolo M, Genevese MC, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 2012;64:617–29.

    Article  PubMed  CAS  Google Scholar 

  12. • Kremer JM, Cohen S, Wilkinson BE, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690-550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 2012;64:970–81. One of the first papers evaluating tofactinib in RA, here in methotrexate incomplete responders.

    Article  PubMed  CAS  Google Scholar 

  13. Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH. Tofacitinib study investigators. Phase II study of tofacitinib (CP-690-550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res. 2011;63:1150–8.

    Article  CAS  Google Scholar 

  14. • Fleischmann R, Kremer JM, Cush J, ORAL Solo investigators, et al. Placebo controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495–507. Another early study evaluating tofactinib monotherapy in RA.

    Article  PubMed  CAS  Google Scholar 

  15. Van Vollenhoven RF, Fleischmann R, Cohen S, ORAL Standard investigators, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508–19.

    Article  PubMed  Google Scholar 

  16. • Burmester GB, Blanco R, Charles-Schoeman C, ORAL Step investigators, et al. Tofacitinib (CP-690-550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomized phase 3 trial. Lancet. 2013;381(9865):451–60. The initial study evaluating tofactinib in TNF-inhibitor incomplete responders.

    Article  PubMed  CAS  Google Scholar 

  17. • der Heijde V, Tanaka Y, Fleischmann R, ORAL Scan investigators, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis on methotrexate: 12-month data from a 24-month Phase 3 randomized radiographic study. Arthritis Rheum. 2013;65:59–570. A large study evaluating the efficacy, including radiographic effects, of tofactitinib in RA patients who weremethotrexate incomplete responders.

    Article  Google Scholar 

  18. Kremer J, Li ZG, Hall S, ORAL Scan investigators, et al. Tofacitinib (CP-690,550), an oral JAK inhibitor in combination with traditional DMARDs: Phase 3 study in patients with active rheumatoid arthritis with inadequate response to DMARDs. Ann Rheum Dis. 2011;70(Supp13):170. abstract LB005.

    Google Scholar 

  19. Lee BL, Fleischmann RM, Hall S, et al. Radiographic, clinical and functional comparison of tofacitinib monotherapy versus methotrexate in methotrexate naïve patients with rheumatoid arthritis. Arthritis Rheum. 2012;64(Suppl):1049. abstract 2486.

    Google Scholar 

  20. Winthrop KL, Park SH, Gul A, et al. Tuberculosis in patients with rheumatoid arthritis. Arthritis Rheum. 2012;64(Supp):547. abstract 1278.

    Google Scholar 

  21. Winthrop KL, Valdez H, Mortensen E, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheum. 2012;64(Supp):1051. abstract 2490.

    Google Scholar 

  22. Ahadieh S, Checchio T, Tensfeldt T, et al. Meta-analysis of malignancies, serious infections, and serious aderse events with tofacitinib or biologic treatment in rheumatoid arthritis clinical trials. Arthritis Rheum. 2012;64(Supp):726. abstract 1697.

    Google Scholar 

  23. Vanhoutte F, Mazur M, Van der Aa A, et al. Selective JAK1 inhibition in the treatment of rheumatoid arthritis: proof of concept with GLPG0634. Arthritis Rheum. 2012;64(Supp):1051. abstract 2489.

    Google Scholar 

  24. Zhu T, Oda K, Valluri U, et al. Coadministration of ASP015K, a novel janus kinase inhibitor with methotrexate demonstrates tolerability and lack of pharmacokinetic interactions in patients with rheumatoid arthritis. Arthritis Rheum. 2012;64(Supp):569. abstract 1322.

    Google Scholar 

  25. Keystone E, Taylor P, Genevese, et al. 12-week results of a phase 2b dose-ranging study of LY3009104 (INCB028050), an oral JAK1/JAK2 inhibitor, in combination with traditional DMARDs in patients with rheumatoid arthritis. Ann Rheum Dis. 2012;71(Supp):666. abstract LB005.

    Google Scholar 

  26. Greenwald MW, Fidelus-Gort R, Levy R, et al. A randomized dose-ranging, placebo controlled study of INCB028050, a selective JAK1 and JAK2 inhibitor in subjects wit activeh rheumatoid arthritis. Arthritis Rheum. 2010;62(Supp):911. abstract 2172.

    Google Scholar 

  27. Genevese M, Keystone E, Taylor P, et al. 24-week results of a blinded phase 2b dose-ranging study of baracitinib, an oral janus kinase 1/janus kinase 2 inhibitor, in combination with traditional disease modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Rheum. 2012;64(Supp):1049. abstract 2487.

    Google Scholar 

  28. Pine PR, Chang B, Schettler N, et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol. 2007;124:244–57.

    Article  PubMed  CAS  Google Scholar 

  29. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, et al. Treatment of rheumatoid arthritis with a Syk inhibitor: a twelve week, randomized, placebo-controlled trial. Arthritis Rheum. 2008;58:3309–18.

    Article  PubMed  CAS  Google Scholar 

  30. • Weinblatt ME, Kavanaugh A, Genevese MC, et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med. 2010;363:1303–12. One of the initial trials evaluating fostamatinib in RA.

    Article  PubMed  CAS  Google Scholar 

  31. • Genovese MC, Kavanaugh A, Weinblatt ME, et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three month randomized, placebo controlled phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum. 2011;63:337–45. Another early trial evaluating fastamitinb in RA.

    Article  PubMed  CAS  Google Scholar 

  32. •• Boers M. Syk kinase inhibitors for rheumatoid arthritis: trials and tribulations. Arthritis Rheum. 2011;63:329–30. A good review of issues of study design in RA trials, focusing on the initial fostamatinib clinical trials.

    Article  PubMed  Google Scholar 

  33. Schett G, Zweina J, Firestein G. The p-38 mitogen-activated protein kinase )MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis. 2008;67:909–16.

    Article  PubMed  CAS  Google Scholar 

  34. Cohen SB, Cheng TT, Chindalore V, et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum. 2009;60:335–44.

    Article  PubMed  CAS  Google Scholar 

  35. Genovese MC. Inhibition of p38: has the fat lady sung? Arthritis Rheum. 2009;60:317–20.

    Article  PubMed  Google Scholar 

  36. Kay J, Morales R, Bellatin L, et al. Treatment of rheumatoid arthritis (RA) with a MEK kinase inhibitor: results of a 12 week, randomized, placebo-controlled phase 2 study in patients with active rheumatoid arthritis on a background of methotrexate. Ann Rheum Dis. 2010;69: abstract 0P0013.

  37. Stock TC, Bloom BJ, Wei N, et al. Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol. 2012;39:720–7.

    Article  PubMed  CAS  Google Scholar 

  38. Fleischmann R, Poiley J, Stoiilov R, et al. The oral S1P lyase inhibitor (LX2931) demonstrates favorable safety and potential benefit at 12 weeks in a phase 2 proof-of-concept trial in patients with active rheumatoid arthritis on stable methotrexate therapy. Ann Rheum Dis. 2011;70, abstract OP0059.

  39. Amoroso A, Hafsi S, Militello L, et al. Understanding rituximab function and resistance: implications for therapy. Front Biosci. 2011;16:770–82.

    Article  CAS  Google Scholar 

  40. Herrero-Beaumont G, Martinez Calatrava M, Castaneda S. Abatacept mechanism of action: concordance with its clinical profile. Rheumatol Clin. 2012;8:78–83.

    Google Scholar 

  41. •• Bluml S, Scheinecker C, Smolen JS, Redlich K. Targeting TNF receptors in rheumatoid arthritis. Int Immunol. 2012;24:275–81. A comprehensive review of the immunologic effects of TNF inhibition.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Edward Keystone has received research funding from Abbott Laboratories, Amgen, AstraZeneca, Bristol–Myers Squibb, F. Hoffmann–La Roche, Janssen Pharmaceutica, Eli Lilly and Company, Novartis, Pfizer, and UCB; has served as a consultant and/or on advisory boards for Abbott Laboratories, AstraZeneca, Biotest, Bristol–Myers Squibb, F. Hoffmann–La Roche, Genentech, Janssen Pharmaceutica, Eli Lilly and Company, Merck and Co., Nycomed, Pfizer, and UCB; and has received speaker honoraria from Abbott Laboratories, AstraZeneca, Bristol–Myers Squibb Canada, F. Hoffmann–La Roche, Janssen Pharmaceutica, Pfizer, UCB, Amgen, and Abbott Pharmaceuticals. Marc D. Cohen declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. The Rebecca MacDonald Centre for Arthritis and Autoimmune Diseases, Mount Sinai Hospital, 60 Murrray St., Room 2-006, Box 4, Toronto, Ontario, M5T 379, Canada

    Edward Keystone

  2. Rheumatology, University of Colorado Health Sciences Center, 668 Humboldt St, Denver, CO, 80218, USA

    Marc D. Cohen

Authors
  1. Edward Keystone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marc D. Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edward Keystone.

Additional information

This article is part of the Topical Collection on Rheumatoid Arthritis

Rights and permissions

Reprints and permissions

About this article

Cite this article

Keystone, E., Cohen, M.D. Cell-Signaling Therapy in Rheumatoid Arthritis. Curr Rheumatol Rep 15, 368 (2013). https://doi.org/10.1007/s11926-013-0368-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-013-0368-5

Keywords

Search

Navigation